


3 Stocks To Buy 2019

UK Equities

One Financial Markets is the trading name of C B Financial Services Ltd, a company registered in England with company number 6050593. C B Financial Services Ltd is authorised and regulated by the Financial Conduct Authority in the UK (under firm reference number 466201) and the Financial Sector Conduct Authority in South Africa (with FSP number 45784).

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. **67% of retail investor accounts lose money when trading CFDs with this provider.** You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.



Trading near a record high, a 3.6% dividend, dollar earning, Brexit immune - the only way is up?

By market capitalisation AstraZeneca resides in the Top 10 of global pharmaceutical companies. Equally impressive is its 3.6% dividend payment and capacity for share price growth - a combination seldom seen.

Shares in AstraZeneca have gained a remarkable 50% in just over 2 years to reach a record price of 6540p. The company has the world's two largest economies to thank for this, with a combined 51% of sales coming from the U.S. and China (sales from the latter grew 28% in Q1 2019 alone).

Only 21% of sales come from Europe ensuring Brexit turmoil should have limited impact. On the subject of Brexit, the company said it has extensively prepared for UK's anticipated exit from the European Union, even in the event of a no-deal exit.

Q1 sales were recorded at \$5.47bn, ahead of expectations, benefitting from higher demand for its cancer medicines and the recent acquisition of Japan's Daiichi Sankyo.

With Brexit and U.S.-China trade talks set spark volatility in the second half of 2019, AstraZeneca's qualities may prove more desirable than usual.

Reassess at 5300p – This price would represent a near 1-year low.

BUY
AstraZeneca Plc - current price 6050p

Background
AstraZeneca Plc researches, manufactures, and sells pharmaceutical and medical products. in eight therapeutic areas, including gastrointestinal, oncology, cardiovascular, respiratory, central nervous system, pain control, anaesthesia, and infection.

Listing	Market Cap	52-week range	Dividend yield
FTSE 100	£79.3bn	5110p - 6540p	3.6%

Analyst Ratings
A collection of current ratings (Buy/Hold/Sell) issued by city analysts, accompanied by the average 12-month target price. Data compiled by Bloomberg.

BUY ratings	HOLD ratings	SELL ratings	12-month av. TP
20	10	3	6573p (+8.6%)

Technical Levels
Potential support level 5500p / Potential resistance level 6540p



Support and resistance levels are prices at which a stock stops declining (finds support) and stops rising (finds resistance), these levels are derived from historical price analysis and are often considered when identifying future prices at which to buy and sell.